FILTER

Refine your search with the following facets to narrow down your results.

6 Current news of NovImmune

Genentech Initiates First-in-Human Study with NovImmune’s Anti-IL17 Antibody

19-Dec-2011 - NovImmune announced that Genentech, a member of the Roche Group, initiated a First-in-Human study with anti-IL-17 (NI-1401, RG7624), a fully human monoclonal antibody designed to specifically and selectively bind to the human IL-17 family of cytokines. The anti-IL-17 antibody was generated at ...

cytokines Genentech milestone payments +2

NovImmune Initiates a Proof-of-Concept Study in Primary Biliary Cirrhosis (PBC)

26-Sep-2011 - NovImmune announced that a Proof-of–Concept (PoC) study with NI-0801, a fully human monoclonal antibody neutralizing the CXCL10/Interferon-gamma-inducible protein-10 (IP-10) chemokine, was initiated in patients with PBC. This is a chronic inflammatory, debilitating condition of the bile ducts ...

bile ducts cirrhosis hepatology +3

NovImmune Nominates Klaus Strein as New Member of the Board of Directors

27-May-2011 - NovImmune announced that Klaus Strein was nominated member of the Board of Directors.Prof Klaus Strein holds a Ph.D. in chemistry from the University of Heidelberg and is also qualified as an M.D. specialized in pharmacology and toxicology. Prof Strein joined Boehringer Mannheim (BM) as Head of ...

Board of Directors

NovImmune enters exclusive antibody licensing agreement with Genentech

27-Jul-2010 - NovImmune announced that it successfully entered into an exclusive licensing agreement with Genentech Inc. a member of the Roche Group for a proprietary anti-IL-17 fully human monoclonal antibody, and access to back-up antibodies. Recently, the IL-17 signaling pathway has received significant ...

antibodies autoimmune diseases biology +2

NovImmune successfully completes NI-0801 Phase I clinical study

14-Jul-2009 - NovImmune announced the successful completion of the first phase I clinical study with its fully human monoclonal antibody NI-0801 targeting the chemokine IP-10 (CXCL10) in healthy volunteers. The randomized, double-blinded, placebo controlled, single centre, phase I study of escalating single ...

atherosclerosis chemokines colitis ulcerosa +9

Panspecific antibodies: Novimmune successful in multiple specificities

21-Apr-2009 - NovImmune announced the description of a single antibody engineered for double antigen binding specificity involving chemokines as targets. The work was accepted for publication in mAbs. Antibodies are designed by nature to bind to epitopes on pathogens with high capacity through a unique one ...

antibodies Binding Site chemokines +4